Gross Profit Comparison: United Therapeutics Corporation and Evotec SE Trends

Pharma Giants' Profit Growth: 2014-2023

__timestampEvotec SEUnited Therapeutics Corporation
Wednesday, January 1, 2014293780001162636000
Thursday, January 1, 2015379870001396725000
Friday, January 1, 2016585540001526100000
Sunday, January 1, 2017825680001619600000
Monday, January 1, 20181120160001429100000
Tuesday, January 1, 20191328910001331200000
Wednesday, January 1, 20201257430001375200000
Friday, January 1, 20211515430001563000000
Saturday, January 1, 20221740650001789600000
Sunday, January 1, 20231750510002070000000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Companies: Gross Profit Trends from 2014 to 2023

In the competitive landscape of the pharmaceutical industry, United Therapeutics Corporation and Evotec SE have showcased distinct growth trajectories over the past decade. From 2014 to 2023, United Therapeutics Corporation consistently outperformed Evotec SE in terms of gross profit, with a remarkable increase of approximately 78% over this period. Starting at a gross profit of around $1.16 billion in 2014, United Therapeutics reached an impressive $2.07 billion by 2023. In contrast, Evotec SE, while showing steady growth, expanded its gross profit by nearly 500%, from $29 million in 2014 to $175 million in 2023. This stark contrast highlights the diverse strategies and market positions of these two companies. As the pharmaceutical sector continues to evolve, these trends offer valuable insights into the financial health and strategic direction of these industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025